Citadel Advisors’s Twist Bioscience TWST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$58M Buy
1,220,400
+1,188,351
+3,708% +$53.3M 0.01% 1226
2025
Q4
$1.02M Sell
32,049
-83,196
-72% -$2.6M ﹤0.01% 7362
2025
Q3
$3.24M Sell
115,245
-1,388,301
-92% -$42M ﹤0.01% 5160
2025
Q2
$55.3M Buy
1,503,546
+432,280
+40% +$14.9M 0.01% 1168
2025
Q1
$42.1M Sell
1,071,266
-330,991
-24% -$14.9M 0.01% 1283
2024
Q4
$65.2M Sell
1,402,257
-80,299
-5% -$3.63M 0.01% 1045
2024
Q3
$67M Buy
1,482,556
+54,746
+4% +$2.6M 0.01% 980
2024
Q2
$70.4M Sell
1,427,810
-284,635
-17% -$11.6M 0.01% 882
2024
Q1
$58.8M Sell
1,712,445
-127,171
-7% -$4.59M 0.01% 1081
2023
Q4
$67.8M Buy
1,839,616
+281,165
+18% +$6.5M 0.01% 954
2023
Q3
$31.6M Sell
1,558,451
-6,276
-0.4% -$138K 0.01% 1457
2023
Q2
$32M Buy
1,564,727
+390,899
+33% +$5.86M 0.01% 1420
2023
Q1
$17.7M Buy
1,173,828
+608,802
+108% +$13.4M ﹤0.01% 2053
2022
Q4
$13.5M Buy
565,026
+497,109
+732% +$14.4M ﹤0.01% 2422
2022
Q3
$2.39M Sell
67,917
-410,309
-86% -$17.4M ﹤0.01% 5249
2022
Q2
$16.7M Buy
478,226
+271,200
+131% +$9.61M ﹤0.01% 2037
2022
Q1
$10.2M Buy
207,026
+21,006
+11% +$1.16M ﹤0.01% 2916
2021
Q4
$14.4M Buy
186,020
+103,007
+124% +$10.6M ﹤0.01% 2484
2021
Q3
$8.88M Buy
83,013
+78,595
+1,779% +$9M ﹤0.01% 3271
2021
Q2
$589K Buy
4,418
+480
+12% +$55.8K ﹤0.01% 9666
2021
Q1
$488K Sell
3,938
-343
-8% -$52.1K ﹤0.01% 9727
2020
Q4
$605K Sell
4,281
-12,283
-74% -$1.36M ﹤0.01% 7800
2020
Q3
$1.26M Sell
16,564
-41,296
-71% -$2.57M ﹤0.01% 5610
2020
Q2
$2.62M Buy
+57,860
New +$2.08M ﹤0.01% 4099
2020
Q1
Sell
-146,802
Closed -$3.08M 10202
2019
Q4
$3.08M Buy
146,802
+55,525
+61% +$1.3M ﹤0.01% 3745
2019
Q3
$2.18M Buy
+91,277
New +$2.65M ﹤0.01% 4348

Other funds holding TWST

Citadel Advisors's TWST Position: Q1 2026 in Review

Citadel Advisors increased its Twist Bioscience (TWST) stake by 3,708% in Q1 2026, buying an estimated $53.3M and bringing the position to 1,220,400 shares worth $58M. The position accounts for 0.01% of the portfolio, ranked #1226.

Citadel Advisors first reported a position in TWST in Q3 2019 and has held it in 26 quarters since. The position peaked at $70.4M in Q2 2024. 279 funds tracked by Wall St. Rank hold TWST as of Q1 2026.

  • Citadel Advisors held 1,220,400 shares of Twist Bioscience worth $58M as of Q1 2026.
  • Citadel Advisors bought 1,188,351 Twist Bioscience shares in Q1 2026, an estimated $53.3M.
  • Twist Bioscience made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1226 holding.
  • Citadel Advisors first reported a position in Twist Bioscience in Q3 2019 and has held it in 26 quarters since.
  • Citadel Advisors's Twist Bioscience position peaked at $70.4M in Q2 2024.
  • 279 funds tracked by Wall St. Rank held Twist Bioscience as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.